The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients

The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients

Introduction: Recently, several clinical trials of immunotherapy for extensive-stage small-cell lung cancer (ES-SCLC) have shown limited benefits because of unselected patients. Thus, we aimed to explore whether YES-associated protein 1 (YAP-1) and POU domain class 2 transcription factor 3 (POU2F3)...

Full description

Bibliographic Details
Main Authors: Yu-Qing Chen, Ling-Ling Gao, Ling-Cong Kong, Xu-Hui Guan, Huan Yang, Yu-Fa Li, Zhi-Yi Lv, Xu-Chao Zhang, Hui-Ying Liang, Hua-Jun Chen, Yi-Long Wu, Jie Huang, Jin-Ji Yang
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Small-cell lung cancer
Immunotherapy
YAP-1
POU2F3
ECT
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294223000059

Internet

http://www.sciencedirect.com/science/article/pii/S2468294223000059

Similar Items